PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan

Journal of Critical Care

Volumn 26, Issue 2, 2011, Pages 223.e1-223.e9

  Cook, Deborah ^a   Meade, Maureen ^a   Guyatt, Gordon ^a   Walter, Stephen D ^a   Heels Ansdell, Diane ^a   Geerts, William ^b   Warkentin, Theodore E ^a   Cooper, D Jamie ^c,d   Zytaruk, Nicole ^a   Vallance, Shirley ^c   Berwanger, Otavio ^e   Rocha, Marcelo ^f   Qushmaq, Ismael ^g   Crowther, Mark ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c The Alfred ^*  (Australia)

^d MONASH UNIVERSITY   (Australia)

^e Hospital Do Coração   (Brazil)

^f Santa Casa de Porto Alegre   (Brazil)

^g King Faisal Specialist Hospital and Research Center Jeddah   (Saudi Arabia)

Author keywords

Critical care; Pulmonary embolism; Thromboprophylaxis; Venous thrombosis

Indexed keywords

DALTEPARIN; HEPARIN;

ARTICLE; CLINICAL PROTOCOL; CRITICALLY ILL PATIENT; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBOLISM PREVENTION; FOLLOW UP; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE; LEG THROMBOSIS; LENGTH OF STAY; LUNG EMBOLISM; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PILOT STUDY; PROPHYLAXIS; SENSITIVITY ANALYSIS; THROMBOEMBOLISM; TREATMENT PLANNING;

EID: 79953780315     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2011.02.010     Document Type: Article

References (54)

1. Attia J., Ray J.G., Cook D.J., Douketis J., Ginsberg J.S., Geerts W. Deep vein thrombosis and its prevention in critically ill patients. Arch Intern Med 2001, 161(10):1268-1279.
2. Crowther M.A., Cook D.J., Griffith L.E., et al. Deep venous thrombosis: clinically silent in the intensive care unit. J Crit Care 2005, 20(4):334-340.
3. Crowther M.A., Cook D.J., Griffith L.E., et al. Neither baseline tests of molecular hypercoagulability nor d-dimer levels predict deep venous thrombosis in critically ill medical-surgical patients. Intensive Care Med 2005, 31(1):48-55.
4. Marik P.E., Andrews L., Maini B. The incidence of deep venous thrombosis in ICU patients. Chest 1997, 111:661-664.
5. Cook D.J., Crowther M., Meade M., et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence and risk factors. Crit Care Med 2005, 33(7):1565-1571.
6. McKelvie P.A. Autopsy evidence of pulmonary thromboembolism. Med J Australia 1994, 160:127-128.
7. Moser K.M., LeMoine J.R., Nachtwey F.J., Spragg R.G. Deep venous thrombosis and pulmonary embolism: frequency in a respiratory intensive care unit. JAMA 1981, 246:1422-1424.
8. Hirsch D.R., Ingenito E.P., Goldhaber S.Z. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995, 274:335-337.
9. Douketis J.D., Kearon C., Bates S., Duku E.K., Ginsberg J.S. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998, 279:458-462.
10. Stein P.D., Henry J.W. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995, 108:978-981.
11. Karwinski B., Svendsen E. Comparison of clinical and postmortem diagnosis of pulmonary embolism. J Clin Pathol 1989, 42:135-139.
12. Twigg S.J., McCrirrick A., Sanderson P.M. A comparison of post mortem findings with post hoc estimated clinical diagnoses of patients who die in a United Kingdom intensive care unit. Intensive Care Med 2001, 27:706-710.
13. Clagett G.P., Anderson F.A., Geerts W., Heit J., Knudson M.M., Lieberman J.R., et al. Prevention of venous thromboembolism. Chest 1998, 114:531S-560S.
14. Collins R., Scrimgeour A., Yusuf S., et al. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988, 318(18):1162-1173.
15. Geerts W.H., Bergqviist D., Pineo G.F., Heit J.A., Samama C.M., Lassen M.R., et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence based clinical practice guidelines (8th Edition). Chest 2008, 133:381-453.
16. Cade J.F. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982, 10:448-450.
17. Fraisse F., Holzapfel L., Couland J.M., Simonneau G., Bedock B., Feissel H., et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. Association of Non-University Affiliated Intensive Care Specialist Physicians in France. Am Rev Resp Crit Care Med 2000, 161:1109-1114.
18. De A., Roy P., Garg V.K., et al. Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery. Blood Coagul Fibrinolysis 2010, 21(1):57-61.
19. Shorr A.F., Williams M.D. Venous thromboembolism in critically ill patients. Observations from a randomized trial in sepsis. Thromb Haemost 2009, 101(1):139-144.
20. Cruickshank M.K., Levine M.N., Hirsh J., et al. An evaluation of impedance plethysmography and 125I-fibrinogen leg scanning in patients following hip surgery. Thrombosis & Haemostasis 1989, 62:830-834.
21. Levi M., Levy M., William M.D., Douglas I., Artigas A., Antonelli M., et al. Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated). Am Rev Resp Crit Care Med 2007, 176:483-490. for the Xigris in Prophylactic Heparin Evaluation in Severe Sepsis (XPRESS) Study Group.
22. Geerts W.H., Jay R.M., Code K.I., Chen E., Szalai J.P., Saibil E.A., et al. A comparison of low-dose heparin with low-molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996, 335:701-707.
23. Cook D.J., McMullin J., Hodder R., Heule M., Pinilla J., Dodek P., et al. Prevention and diagnosis of venous thromboembolism in critically ill patients: a Canadian survey. Crit Care 2001, 5(6):336-342. for the Canadian ICU Directors Group.
24. Cooper D.J., Bishop N., Cade J., Finfer S., Gallus A., Myburgh J. Thromboprophylaxis in intensive care patients in Australia and New Zealand: a brief survey report. Crit Care 2005, 20:354-356. for the Australian and New Zealand Intensive Care Society Clinical Trials Group.
25. Cook D.J., Attia J., Weaver B., McDonald E., Meade M., Crowther M. Venous thromboembolic disease: an observational study in medical-surgical intensive care unit patients. J Crit Care 2000, 15(4):127-132.
26. McMullin J.P., Cook D.J., Griffith L.E., McDonald E., Clarke F., Guyatt G.H., et al. Minimizing errors of omission: Behavioural rEenforcement of Heparin to Avert Venous Emboli (BEHAVE). Crit Care Med 2006, 34:694-699.
27. Robertson M.S., Nichol A.D., Higgins A.M., Bailey M.J., Presneill J.J., Cooper D.J., et al. Venous thromboembolism prophylaxis in the critically ill: a point prevalence survey of current practice in Australian and New Zealand intensive care units. Crit Care Resusc 2010, 12(1):9-15. and the VTE Point Prevalence Investigators for the Australian and New Zealand Intensive Care Research Centre (ANZIC-RC) and the Australian and New Zealand Intensive Care Society Clinical Trials Group.
28. Lacherade J.C., Cook D.J., Heyland D., Chrusch C., Brochard L., Brun-Buisson C. Prevention of venous thromboembolism in critically ill medical patients: a Franco-Canadian cross-sectional study. J Crit Care 2003, 18(4):228-237. for the French and Canadian ICU Directors Groups.
29. Tapson V.F., Decousus H., Pini M., Chong B.H., Froehlich J.B., Monreal M., et al. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the international medical prevention registry on venous thromboembolism. Chest 2007, 132:936-945. for the IMPROVE Investigators.
30. Cohen A.T., Tapson V., Bergmann J.F., Goldhaber S.Z., Kakkar A.K., Deslandes B., et al. Venous thromboembolism risk and prophylaxis in the acute hospital setting (ENDORSE Study): a multinational cross-sectional study. Lancet 2008, 371:387-394. for the ENDORSE Investigators.
31. Goldhaber S.Z. Venous thromboembolism in the intensive care unit: the last frontier for prophylaxis. Chest 1998, 113:5-7. [editorial].
32. Lederle F.A. Heparin prophylaxis for medical patients? [editorial]. Ann Intern Med 1998, 128(9):768-770.
33. Evidence Report/Technology Assessment Prevention of venous thromboembolism after injury. Agency for Health Care Policy Research http://www.ahcpr.gov/clinic/vtsumm.htm.
34. Cook D.J., Rocker G., Meade M.O., Guyatt G.H., Geerts W., Anderson D., et al. Prophylaxis of ThromboEmbolism in Critical Care Trials (PROTECT): a pilot study. J Crit Care 2005, 20:364-372. for the PROTECT Investigators and the Canadian Critical Care Trials Group.
35. Arnold D.A., Burns K.E., Adhikari N., Kho M.E., Meade M.O., Cook D.J. The design and interpretation of pilot trials in critical care medicine. Crit Care Med 2009, 36(7):S69-S74.
36. Douketis J., Cook D.J., Meade M., Guyatt G., Geerts W., Skrobik Y.., et al. Renal insuffiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics. The DIRECT (Dalteparin's Influence on REnally Compromised anti-Ten-A) Study. Arch Intern Med 2008, 168(16):1805-1812. for the Canadian Critical Care Trials Group.
37. Van Spaal H.G.C., Torren A., Kiss A., Fowler R. Eligibility criteria of randomized controlled trials published in high impact journals. JAMA 2007, 297:1233-1244.
38. Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(6 Suppl.):340S-380S.
39. Sheridan D., Carter C., Kelton J.G. A diagnostic test for heparin induced thrombocytopenia. Blood 1986, 67:27-30.
40. Arnold D.M., Donahoe L., Clarke F.J., Tkaczyk A.J., Heels-Ansdell D., Zytaruk N., et al. Bleeding during critical illness: a prospective cohort study using a new measurement tool. Clin Invest Med 2007, 30:E93-E102.
41. Cook D.J., Medic A., Andrews J., Schiff D., Dobranowski J., Bates S., et al. Doppler compression ultrasound of the lower extremities in ICU patients: an inter-rater reliability study. Crit Care Med 2003, A:346.
42. Southon J., Zytaruk N., Lim W.P., Zarychanski R., Rocha M., Heels-Ansdell D., et al. Venous thrombosis adjudication for a thromboprophylaxis trial. Hamilton Research Day Abstract Book 2009, for the PROTECT Investigators & Canadian Critical Care Trials Group.
43. Lamontagne F., McIntyre L., Dodek P., Southon J., Zytaruk N., Heels-Ansdell D., et al. Calibration & adjudication of thrombotic events in a thromboprophylaxis trial. Canadian Critical Care Forum Abstract Book 2009, for the PROTECT Investigators and the CCCTG.
44. Zytaruk N., Meade M., Mehta S., Hall R., Southon J., Heels-Ansdell D., et al. Adjudication calibration for pulmonary embolism in a thromboprophylaxis trial. Am J Resp Crit Care Med 2009, 179:A1582. for the PROTECT Investigators and the CCCTG.
45. Arnold D., Rabbat C., Lauzier F., Zytaruk N., Heels-Ansdell D., Cook D.J. Adjudicating bleeding outcomes in a large thromboprophylaxis trial in critical illness. Blood (ASH annual meeting Abstracts) 2009, 114:2471. for the PROTECT Investigators and the CCCTG.
46. Luce J., Cook D.J., Martin T.R., Angus D.C., Boushey H.A., Curtis J.R., et al. The ethical conduct of clinical research involving critically ill patients in the United States and Canada: principles and recommendations. Am J Resp Crit Care Med 2004, 170:1375-1384. for the Writing Committee of the American Thoracic Society Conference on the Ethical Conduct of Clinical Research Involving the Critically Ill. Luce J, Cook DJ, Martin T (Co-chairs).
47. Cook D.J., Lauzier F., Rocha M.G., Sayles M.J., Finfer S. Serious adverse events in academic trials of common drugs in critical care. Can Med Assoc J 2008, 178(9):1181-1184.
48. Baigent C., Harrel F.H., Buyse M., Emberson J.R., Altman D.G. Ensuring trial validity by data quality assurance and diversification of monitoring methods. Sensible guidelines conference. Clinical Trials 2008, 5:49-55.
49. Heels-Ansdell D., Walter S., Guyatt G., Warkentin T., Crowther M., Geerts W., et al. Central statistical monitoring in an international thromboprophylaxis trial. Am J Respir Crit Care Med 2010, 181:A6041. for the PROTECT Investigators, CCCTG and ANZICS-CTG.
50. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet 2005, 365:712-722. DAMOCLES Study Group.
51. Nagge J., Crowther M., Hirsh J. Is impaired renal function a contraindication to the use of low molecular weight heparin?. Arch Intern Med 2002, 162:2605-2609.
52. Rabbat C., Cook D.J., Crowther M.A., McDonald E., Clarke F., Meade M.O., et al. Dalteparin thromboprophylaxis for critically ill medical-surgical patients. J Crit Care 2005, 20:357-363.
53. Haybittle J.L. Repeated assessment of results in clinical trials of cancer treatment. British J Radiology 1971, 44:793-797.
54. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., et al. Design and analysis of randomized clinical trials requiring prolonged observations of each patient. I. Introduction and design. Br J Cancer 1976, 34:585-612.